Worth a listen! 🎙️ As we head into ASCO, here's a great podcast from @drkarenknudsen.bsky.social who brilliantly describes the state of cancer therapy development and the need for more translational resources to bring discoveries to patients faster. www.biocentury.com/article/6594...

Mind the gap: Parker Institute’s Knudsen points to urgent need to fix translation

Karen Knudsen, CEO of the Parker Institute for Cancer Immunotherapy, believes the central problem in cancer drug development is not discovery, but a broke...

biocentury.com

Thank you Mark Foundation (@themarkfdn.bsky.social) for supporting our founder Hani Goodarzi (@genophoria.bsky.social) and team on his paper about our novel oncRNA biology. This research is foundational to Exai Bio where we develop AI models targeting oncRNAs to detect disease earlier.

Q1 2026 Mark Foundation-Supported Publications Advance Cancer Science | The Mark Foundation for Cancer Research

The year is off to a strong start for Mark Foundation investigators! In the first quarter, their Foundation-funded research has led to dozens of peer-reviewed papers spanning the full spectrum of…

themarkfoundation.org

Inspirational story from our friends and collaborators about the need to push the system harder to find cures for rare cancers. At Exai, we are developing AI models to make high quality, data driven diagnostic solutions accessible for all. centuryofbio.com/p/sid?utm_me...

Going Founder Mode On Cancer

Sid Sijbrandij's extraordinary care journey

centuryofbio.com

That’s a wrap on #SABCS25! Thank you to Dr. Lee Schwartzberg for presenting data demonstrating our platform’s ability to detect early stage breast cancer with high accuracy. #AI #RNA #earlydetection Learn more here: www.exai.bio/publications...

Yesterday our co-founder and CSO @babak-a.bsky.social presented at the Biotech-Pharma Statistics Workshop (BBSW) about the powerful combination of AI and cell-free RNA to detect early-stage lung cancer in the blood.

We’re excited to welcome Michael Nall as CEO and Board Director and new Board Directors - Steve Kafka, PhD, of S32, Dusan Perovic of Two Sigma Ventures and Emir Sandhu, MD, of Blue Venture Fund. Their leadership will be invaluable as we advance our RNA & AI liquid biopsy platform.

Reflecting on a productive week of meetings at ASCO! Thank you to all those who visited our Innovation Hub booth to learn more about our technology. #ASCO25 #LiquidBiopsy #AI #RNA

Congratulations to our Board Director Karen Knudsen MBA PhD for receiving the 2025 Allen Lichter Visionary Leader Award from American Society of Clinical Oncology (ASCO). We are so grateful for your leadership, passion and the profound impact you have on the cancer community. #ASCO25 #Leadership

💥New Publication Alert in Clinical Cancer Research💥 We are thrilled to announce our latest publication on our novel RNA and generative AI liquid biopsy platform for early colorectal cancer detection. #EarlyDetection #LiquidBiopsy #RNA Read the full publication here: aacrjournals.org/clincancerre...

Exai Bio presented new data demonstrating the power of its RNA and AI based liquid biopsy platform to detect colorectal cancer. Stage I sensitivity in an independent cohort was 80%, exceeding other blood based approaches. Thanks to Amir Momen-Roknabadi for representing Exai Bio at #AACR25!

DYK almost half of all women have dense breast tissue which means they are at higher risk of developing breast cancer? Exai is joining My Density Matters to spread awareness that today is Find Out My Breast Density Day. Talk to your doctor if you have questions. #BreastDensity #EarlyDetection

Together we unite to fight cancer and inspire hope. #WorldCancerDay #UnitedByUnique #EarlyDetection #BreastCancer

Congratulations to our Board Director Karen Knudsen for receiving the 2025 Allen Lichter Visionary Leader Award from American Society of Clinical Oncology (ASCO). Your tremendous leadership and dedication continue to make a profound impact on cancer care. #ASCO25 connection.asco.org/do/asco-cong...

Our own Mehran Karimzadeh wrote a blog post about our recent Nature Communications publication demonstrating superior cancer detection performance by Exai’s AI platform compared to traditional machine learning methods. #AI #EarlyDetection #LungCancer communities.springernature.com/posts/behind...

Behind the paper: Deep generative AI models analyzing circulating orphan non-coding RNAs enable detection of early-stage lung cancer

Our recent study in Nature Communications highlights the success of a custom generative AI framework in detecting non-small cell lung cancer and its subtypes from serum-derived orphan non-coding RNAs.

communities.springernature.com

Today, we honor the legacy of Dr. Martin Luther King Jr., whose words continue to inspire: “The time is always right to do what is right.” At Exai, we are committed to doing what is right—advancing cancer detection and ensuring a future where everyone has access to early detection and better health.

We are honored to welcome Karen E. Knudsen, MBA, PhD, to our board of directors. As an internationally recognized oncology leader and immediate past CEO of the American Cancer Society and its advocacy affiliate ACS CAN, Karen is deeply committed to ending cancer as we know it.

💥New Publication Alert in Nature Communications 💥 Our latest publication features our novel generative AI platform, showcasing superior performance in detecting lung cancer compared to traditional machine learning methods. Read the full publication here: www.nature.com/articles/s41...

Deep generative AI models analyzing circulating orphan non-coding RNAs enable detection of early-stage lung cancer

Nature Communications - A generative AI model, Orion, learns a robust and generalizable pattern of non-small cell lung cancer from cancer-specific circulating non-coding RNAs. Orion enhances the...

nature.com

Exai was proud to be part of the inaugural RISE UP For Breast Cancer Meeting hosted by UCSF. #breastcancer #womenshealth #UCSF

3 years of innovation never looked so sweet! Celebrating Exai’s 3rd anniversary today, one donut (and breakthrough) at a time! #lifeatexai

Exai was proud to attend #ESMO2024, where we announced new data demonstrating the ability of our RNA liquid biopsy platform to determine breast cancer tumor ER and HER2 status. #liquidbiopsy #breastcancer

Join us at #ESMO2024 where Exai will present new data demonstrating the ability of our RNA liquid biopsy platform to determine breast cancer tumor ER and HER2 status. #liquidbiopsy #breastcancer

We’re excited to announce Dave Daly has been appointed as Exai Bio’s CEO. Dave brings more than 30 years of extensive cancer diagnostics and executive leadership experience to lead the next chapter of Exai. www.exai.bio/news/exai-bi...

Exai celebrates diversity and wishes everyone a very happy Pride Month. #PrideMonth #earlydetection #lifeatexai #MRD

Proud to present our latest RNA- and AI-based #liquidbiopsy research at #ASCO24! #earlydetection #lifeatexai #MRD

Join Exai at #ASCO24 where we will share promising new data. #earlydetection #MRD

Exai co-founder, Hani Goodarzi, in collaboration with Dr. Laura Essserman and Dr. Laura van ‘t Veer from UCSF, posted a preprint, which provides the history of oncRNAs and their power to predict clinical outcomes and monitor disease burden based on the I-SPY 2 Trial. www.biorxiv.org/content/10.1...

The Exai team had a productive week at #AACR24! We were proud to showcase our #liquidbiopsy research in both early cancer detection and MRD.  #earlydetection #lifeatexai #MRD

Today, Exai presents new MRD data at #AACR24: Our onc-RNA- & AI-based #liquidbiopsy platform can accurately predict survival for patients with TNBC with residual disease, suggesting Exai can aid in tailoring adjuvant treatment for TNBC patients. #MRD #lifeatexai www.exai.bio/news/exai-bi...